Objective: The follow-up study of the developmental features of children suffering from breath-holding spells.
Material And Methods: Seventy-two primary school age children suffering from the breath-holding spells were examined. Somatic, neurological and autonomic status has been followed-up and children developmental features have been analyzed. The Achenbach System of Empirically Based Assessment (ASEBA) for children of 6-18 years old, Zakharov and Lavrentieva-Titarenko anxiety tests were used in the work in addition to clinical research methods.
Results: According to the data obtained, 47.2% of children with a history of breath-holding spells suffer from conditions such as somatoform dysfunction of the gastrointestinal tract, tension headache, vegetative and vascular dystonia, dissomnia, emotional lability syndrome.
Conclusion: The presence of breath-holding spells in children can be considered as a predictor of the autonomic dysfunction development, sleep disorders and anxiety disorders in future.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.17116/jnevro202412411276 | DOI Listing |
Epileptic Disord
December 2024
Department of Child and Adolescent Neurology, Nemours Children's Health, Jacksonville, Florida, USA.
Eur J Pediatr
December 2024
Pediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, 249203, India.
A number of randomized-controlled trials (RCTs) have been conducted comparing the efficacy of piracetam with placebo and other medications in children with breath-holding spells (BHS). However, no systematic review has yet collated all this evidence. All RCTs comparing the efficacy and/or safety of piracetam with placebo or other medications in children with BHS were included.
View Article and Find Full Text PDFBr J Hosp Med (Lond)
November 2024
Department of Anesthesiology, Children's Hospital of Fudan University, Shanghai, China.
Neurol Genet
December 2024
From the Institute of Medical Science (M.R.), University of Toronto; Adult Genetic Epilepsy (AGE) Program (M.R., Q.Z.A., F.Q., I.C., A.A., D.M.A.), Krembil Neurosciences Institute, Toronto Western Hospital, University Health Network, Canada; Epilepsy Unit (A.A.-S.), Vithas Clinical Neuroscience Institute, Vithas Madrid University Hospitals; Faculty of Experimental Sciences (A.A.-S.), Francisco de Vitoria University, Madrid, Spain; Department of Drug Design and Pharmacology (A.B.), University of Copenhagen; Department for Genetics and Personalized Medicine (A.B.), Danish Epilepsy Centre, Dianalund; Institute for Regional Health Services (A.B.), University of Southern Denmark, Odense; NYU Langone Epilepsy Center (O.D., F.Q., A.A.); Edmond J. Safra Program in Parkinson's Disease (A.F.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.F., D.M.A.), Department of Medicine, University of Toronto; Krembil Brain Institute (A.F., D.M.A.); Clinical Genetics Research Program (A.S.B.), Centre for Addiction and Mental Health; The Dalglish Family 22q Clinic (A.S.B.), Toronto General Hospital, University Health Network; Department of Psychiatry (A.S.B.), University of Toronto, Ontario; Toronto Congenital Cardiac Centre for Adults (A.S.B.), Division of Cardiology, Department of Medicine, and Department of Psychiatry, University Health Network and Toronto General Hospital Research Institute and Campbell Family Mental Health Research Institute (A.S.B.), Toronto, Ontario, Canada.
Zh Nevrol Psikhiatr Im S S Korsakova
November 2024
Belgorod Children's Regional Hospital, Belgorod, Russia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!